{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-009735","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.600675+00:00","generated_at":"2026-05-15T10:07:20.001486+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Galectin Therapeutics appoints Dr. Henry Brem to board of directors","bullets":["Dr. Henry Brem appointed as independent director effective March 12, 2026.","Brem is a neurosurgeon-scientist at Johns Hopkins and former Director of Neurosurgery.","He brings expertise in translational medicine and clinical development of novel therapies.","Will receive standard non-employee director compensation per existing program.","No reportable transactions between Brem and the company under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-009735","json":"https://secwatch.observer/filing/0001140361-26-009735.json","markdown":"https://secwatch.observer/filing/0001140361-26-009735.md","text":"https://secwatch.observer/filing/0001140361-26-009735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126009735/0001140361-26-009735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126009735/ef20068034_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:07:20.001486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}